Agenda

  • October 19, 2022


  • October 20, 2022


  • How will data impact future medical device development. In this opening keynote conversation, we'll hear from two leaders in the effort to connect medical devices and bolster them with data. Deborah Kilpatrick, a former executive at medical device companies in CardioDx and Guidant, will discuss how the collection, analysis and incorporation of patient data can improve clinical trial testing and speed medical device development.

  • In 2022, Celine Martin assumed the role of Company Group Chairman, Cardiovascular & Specialty Solutions (CSS) Group, with oversight of a portfolio of businesses including Acclarent, Biosense Webster, Cerenovus and Mentor, which represent billions in sales, employs 12,000 people, and touches over a million patients each year. In the three years prior to this appointment, Martin led J&J’s Robotics & Digital Solutions group, which represents the integrated efforts of Auris Health and Verb Surgical. In this conversation, Martin will share insights cleaned from her two-decades plus at J&J and paint the future paths for the CSS group.

  • Penumbra is a leader in the interventional space. In this interview, Sandra Lesenfants, president, interventional, at Penumbra will detail the company's future plans to grow its neurovascular and vascular businesses. Lesenfants joined Penumbra in 2022, previously serving as president of hospital patient monitoring for Philips. She's also held senior roles in Medtronic, Covidien and ev3.
    Prototype & Product Development

  • The supply chain crisis has forced medical device companies to refocus their efforts to finding necessary parts and supplies. In this panel discussion we'll talk with supply chain leaders who are rethinking supplier lists, working with R&D departments, and ensuring that manufacturings have the technology necessary to meet patient needs.
    Manufacturing & Supply Chain

  • What worries VCs the most? In this this conversation we'll talk with venture capitalists about what they need to see and hear from entrepreneurs before committing to a medical device start-up. We'll also talk with active investors about the new approaches, exciting technology and the larger macro concerns like inflation and labor shortages that are built into their investment decisions.
    Innovation & Investment

  • Combining virtual technologies, analytics and artificial intelligence creates the conditions to revolutionize healthcare. Having an enhanced understanding of the human body's complexity – from its DNA to tissues and organs to the organism as a whole – shapes a more patient-centric healthcare model. It also spans to how medical devices are developed, tested and manufactured by making virtual twins of the product, process and even the manufacturing plant.

    The virtual twin delivers the scientific capabilities for Life Sciences companies to operate more sustainably and create highly effective therapies to meet society’s growing demands, resulting in great impacts to society, which demands access to safe, effective and affordable therapies. Virtual twins bring devices to market faster and more cost-efficiently. Join us to learn how each stage of the product life cycle can be driven by the virtual twin experience.
    Prototype & Product Development

  • Medical device companies are under increasing pressures to bring new products to market faster while facing competing priorities between revenue, innovation development, and emerging competitors. In order to thrive, you need sound commercialization tactics to create internal alignment, respond to external threats, and launch as quickly as possible without sacrificing product compliance, safety, or efficacy. In this dynamic environment, is your go-to-market strategy bulletproof?
    Manufacturing & Supply Chain

  • So you've got investors committed to your company. Now what? In this conversation, we'll hear from advisors, experts and a CEO start-up executives about what it will take to build a start-up that's capable of matching and exceeding expectations. Panelists bring insights to engineering, innovation, fund-raising and creating real company value.
    Innovation & Investment

  • Intuitive literally built the robotic surgical market that many medical device companies - large and small - have started to enter. In this conversation, we'll learn how Intuitive is shifting from market builder to market leader. How will the company use its innovation and investment powers to not only hold onto what it has but also extend the reach of its robotic systems into other medical specialities.

  • How can AI, wearables, and a digital ecosystem transform the 1.5 billion people living with chronic pain around the world? For nearly six years, Boston Scientific and IBM Research have been at the forefront to revolutionize chronic pain care. By joining forces, they are developing a novel approach that discovers new metrics for pain to objectively measure this invisible condition – all with the ultimate goal to help people living with chronic pain to live their healthiest life.
    New Tools & Technology

  • In an era when many medtech start-ups are proving to be one-hit wonders, failure to develop additional innovations can force an undesirable exit strategy on its leadership and employees. Hear from Pat Stephens, Shockwave Medical’s head of R&D as he shares insights about what has led to the company’s successful transition from start-up to high-growth company, including his strategies for success in sustaining a culture of innovation while managing the challenges of a growing team, mounting R&D programs and narrowing timelines.
    Prototype & Product Development

  • In the high-growth and fast-paced neurovascular market, ideas for new products and therapies are abundant. Dan Volz, President of Medtronic Neurovascular and Derek Crittenden, New Technology and Strategy Manager, will introduce for the first time, a new platform developed to advance innovations in development outside of Medtronic. The presentation will share how Medtronic is collaborating with start-ups, physicians, and other external partners to optimize and create access to neurovascular care for patients around the globe.
    Innovation & Investment

  • Join panelists from, IAR Systems, CSI, and Dojo Five to learn about cybersecurity approaches and practical advice on how to prevent cybersecurity issues from affecting your product. Hear from a full gamut of experts ranging from wireless (BLE, WiFi, Cellular), compiler, secure boot, toolchain, design, testing, and a medical product company on how to protect modern medical products.
    Prototype & Product Development

  • The collision of the software and data based artificial intelligence industry with the physical product based medical device industry has created a host of novel IP and legal considerations that companies operating at the intersection of these two industries must consider. This presentation will discuss IP protection and enforcement strategies, as well as other legal considerations / strategies, for companies using artificial intelligence (AI) in the medical device space. AI is an exciting new technology that is revolutionizing many aspects of the medtech field. As just a few examples, medtech companies are using AI to diagnose patients, improve the safety and efficacy of those treatments, improve the manufacturing of medical devices, and much more. And this is just the beginning, as the future use cases and potential of the technology is seemingly unlimited. As medtech companies continue to innovate with AI technologies, it is critical that they take appropriate steps to protect and enforce the valuable intellectual property (IP) they generate. The tools and techniques for protection and enforcement of AI technologies differ somewhat from those used for more traditional medical device technologies. This presentation will explore why that is and provide tips and pitfalls to avoid for companies operating at this dynamic and exciting intersection of AI and medical devices.
    New Tools & Technology

  • In this session, medical device entrepreneurs and executives will learn how to tailor your company’s patent portfolio to protect your company’s investments in innovation based on a survey of your competition, the geographies they operate within, and global patent enforcement options.
    Innovation & Investment

  • The healthcare industry is operating under growing strains brought on by increased demand, worker shortages, and economic pressures. Now more than ever medical device developers need a thorough understanding of clinical perspectives when building new devices. In this panel, we'll talk with medical doctors advising several leading OEMs about how they're serving as a bridge between the medical device industry and surgeons, interventionalists and other healthcare professionals.

  • Outset CEO Leslie Trigg explains why she chose to lead Outset mission to create a dialysis system that restore the freedom lost to the demand of traditional in-clinic dialysis. Outset “enterprise system” for dialysis now allows patients to treat themselves at home when and where they want. Outset experiences can be helpful for other medical device companies working to move care out of clinical settings.

  • Innovation and patient-centric collaboration is fueling the transformation of GI care. The past decade brought exponential growth in new technology for the gastrointestinal field and the next decade will be even more revolutionary. Medtronic Gastrointestinal will share how digital technologies - like Artificial Intelligence - and unprecedented partnerships between industry and clinicians create purpose-built innovations that are empowering physicians to provide better outcomes and experiences for their patients.

  • Zimmer Biomet paved the way to incorporate data-collecting sensors into its orthopedic implants through a ground-breaking partnership with Canary Medical. In this discussion we'll hear from principals at both company about how the collaboration started and, more important, where this use of cutting-edge sensor technology can take the orthopedic implant market.
    New Tools & Technology

  • The $550 billion global medtech industry is becoming connected and digitized at an unprecedented rate, posing challenges for regulatory agencies and payers that often lack the expertise and capacity to keep pace with rapidly evolving technologies. To assess the current regulatory landscape for medtech and digital innovation, BCG and UCLA Biodesign collaborated on a research project examining the review process for medical device registrations. UCLA Biodesign surveyed more than 100 senior executives at medtech companies, representing 105 successful medical product registrations between 2010 and 2021. We'll discuss the results - and their impact - in this session.
    Regulatory & Reimbursment

  • Dialysis involves diverse users from patients to nurses to service professionals across many care settings. It’s with that in mind that the cross- functional development teams at Outset utilized an iterative human-centered design process to develop and evolve the Tablo® Hemodialysis System and its digital ecosystem, putting the end-user first. In this talk, product leaders will discuss how Tablo has become an all-in-one enterprise solution that is connected, intelligent, and easy to learn and use delivering safe and effective care while delighting its users from the ICU to the living room.
    Prototype & Product Development

  • Each year, the FDA processes hundreds of thousands of medical device reports concerning reports of alleged device-related injuries, deaths and malfunctions. We will examine the auspices of the FDA Medical Device Report (MDR) scheme and the mandatory reporting requirements. We will then discuss preparation of relevant systems and protocols to provide manufacturers, distributors and importers with best practices. We will also examine the Voluntary Malfunction Summary Reporting Program (VMSR) and other proactive approaches to mitigate risk.
    Regulatory & Reimbursment

  • Procedures are becoming more complex, creating the need for healthcare providers and MedTech companies to seek digital strategies to gain efficiencies, expand reach and work smarter together. Join Avail CEO Daniel Hawkins, President Ryan Magnes, and CTO James Domine, with their combined medical device and traditional Silicon Valley tech expertise, in a conversation about Remote Collaboration and how MedTech is leveraging this digital capability throughout the product lifecycle – from R&D through product launch and ongoing support. During the session, Avail will share how being part of procedures more often is delivering better insights, time and cost savings, and enhanced relationships with physician customers, and how it’s possible to leverage the speed and innovation of traditional Silicon Valley tech into the healthcare technology industry.
    Prototype & Product Development

  • The human body is an engineering marvel. Technology can channel the power of electrical currents to promote healing – and what if we could direct those signals to help address debilitating medical conditions, such as chronic pain, depression, and cancer? The impact technology has on healthcare continues to accelerate exponentially, making future possibilities limitless. Medtronic will share some examples of these possibilities, the path healthcare technology is on to engineer the extraordinary, and the potential impact on our future – all thanks to the power of electricity.

  • Breakthrough innovations require creativity and persistence. Luckily, the teams of pioneering researchers, scientists and doctors who developed Abbott's industry-changing products like MitraClip that repairs a leaky heart valve, AVEIR VR leadless pacemaker system to treat slow heart rhythms, and Ultreon imaging software that uses artificial intelligence (AI) to view coronary blood flow and blockages, had a large supply of both. Panelists will discuss how the treatment of heart conditions has been revolutionized with the introduction of devices that address unmet needs and go beyond where existing solutions leave off. Learn what goes into designing and bringing to market a game-changing product that can help people with debilitating heart conditions live better lives. Also, find out what the future of heart health technology could look like. And what's even more exciting is that much of that medical device innovation is happening right in the Bay Area.

  • What does the advent of AI, bioelectronic medicine, surgical robotics, remote technologies and other new applications mean for the future of medical device development? In this panel discussion, we'll talk with technology leaders who are responsible for the next generation of medical devices. We'll work to understand the challenges of building medical devices today and what steps they're taking to prepare for tomorrow.